| Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data FC Bidard, DJ Peeters, T Fehm, F Nolé, R Gisbert-Criado, D Mavroudis, ... The lancet oncology 15 (4), 406-414, 2014 | 1040 | 2014 |
| Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative … FC Bidard, VG Kaklamani, P Neven, G Streich, AJ Montero, F Forget, ... Journal of Clinical Oncology 40 (28), 3246-3256, 2022 | 732 | 2022 |
| ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group J Pascual, G Attard, FC Bidard, G Curigliano, L de Mattos-Arruda, ... Annals of Oncology 33 (8), 750-768, 2022 | 644 | 2022 |
| Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized … JY Pierga, FC Bidard, C Mathiot, E Brain, S Delaloge, S Giachetti, ... Clinical Cancer Research 14 (21), 7004-7010, 2008 | 462 | 2008 |
| Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle L De Mattos-Arruda, B Weigelt, J Cortes, HH Won, CKY Ng, P Nuciforo, ... Annals of oncology 25 (9), 1729-1735, 2014 | 455 | 2014 |
| Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer WJ Janni, B Rack, LWMM Terstappen, JY Pierga, FA Taran, T Fehm, ... Clinical Cancer Research 22 (10), 2583-2593, 2016 | 435 | 2016 |
| Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays AE Saliba, L Saias, E Psychari, N Minc, D Simon, FC Bidard, C Mathiot, ... Proceedings of the National Academy of Sciences 107 (33), 14524-14529, 2010 | 429 | 2010 |
| High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for … JY Pierga, D Hajage, T Bachelot, S Delaloge, E Brain, M Campone, ... Annals of oncology 23 (3), 618-624, 2012 | 343 | 2012 |
| Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis FC Bidard, S Michiels, S Riethdorf, V Mueller, LJ Esserman, A Lucci, ... JNCI: Journal of the National Cancer Institute 110 (6), 560-567, 2018 | 333 | 2018 |
| A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1) H Bonnefoi, T Grellety, O Tredan, M Saghatchian, F Dalenc, A Mailliez, ... Annals of Oncology 27 (5), 812-818, 2016 | 326 | 2016 |
| Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types R Lebofsky, C Decraene, V Bernard, M Kamal, A Blin, Q Leroy, TR Frio, ... Molecular oncology 9 (4), 783-790, 2015 | 320 | 2015 |
| Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer F Riva, FC Bidard, A Houy, A Saliou, J Madic, A Rampanou, C Hego, ... Clinical chemistry 63 (3), 691-699, 2017 | 311 | 2017 |
| Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study L Cabel, F Riva, V Servois, A Livartowski, C Daniel, A Rampanou, O Lantz, ... Annals of Oncology 28 (8), 1996-2001, 2017 | 309 | 2017 |
| Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer FC Bidard, C Mathiot, S Delaloge, E Brain, S Giachetti, P De Cremoux, ... Annals of Oncology 21 (4), 729-733, 2010 | 306 | 2010 |
| The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper M Cristofanilli, JY Pierga, J Reuben, A Rademaker, AA Davis, DJ Peeters, ... Critical reviews in oncology/hematology 134, 39-45, 2019 | 302 | 2019 |
| Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials FC Bidard, T Fehm, M Ignatiadis, JB Smerage, C Alix-Panabières, ... Cancer and Metastasis Reviews, 1-10, 2012 | 295 | 2012 |
| Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a … FC Bidard, AC Hardy-Bessard, F Dalenc, T Bachelot, JY Pierga, ... The Lancet Oncology 23 (11), 1367-1377, 2022 | 293 | 2022 |
| Circulating tumor cells: clinical validity and utility L Cabel, C Proudhon, H Gortais, D Loirat, F Coussy, JY Pierga, FC Bidard International journal of clinical oncology 22 (3), 421-430, 2017 | 257 | 2017 |
| Circulating tumor cells in breast cancer FC Bidard, C Proudhon, JY Pierga Molecular oncology 10 (3), 418-430, 2016 | 247 | 2016 |
| Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma FC Bidard, J Madic, P Mariani, S Piperno‐Neumann, A Rampanou, ... International journal of cancer 134 (5), 1207-1213, 2014 | 244 | 2014 |
